An in-depth analysis of hirschsprung’s disease. understanding pathophysiology, diagnosis, and treatment approaches

Nº DE DOI: 10.34896/RSI.2025.74.63.001

AUTHORS

1. Carlos Adán Martin López. General Practitioner. Attached to the Junquillal Health Center of Canton Salitre. Independent Researcher of the Research and Teaching Department Matilde Hidalgo of Procel. Graduate of the University of Guayaquil. (Salitre -Ecuador). https://orcid.org/0009-0005-4022-5305
2. Anabell Stefany Bazurto Litardo. General Practitioner. Attached to the General Monte Sinai Hospital. Graduated of the University of Guayaquil. (Guayaquil-Ecuador). https://orcid.org/0009-0000-4025-082X
3. Lizeth Alejandra Navas Balarezo. General Practitioner. Attached to the Ambato General Hospital. Graduated from the Superior Polytechnic School of Chimborazo. (Riobamba-Ecuador). https://orcid.org/0009-0002-4978-593X
4. Liseth Lorena Espin Gavilanes. General Practitioner. Attached to Private Medical Centers of Ecuador. Graduated from the Central University of Ecuador. (Quito-Ecuador). https://orcid.org/0000-0002-1074-1940
5. Johanna Carolina Pinto Pérez. General Practitioner. Attached to the Carlos Andrade Marin Specialties Hospital. Graduated from the Central University of Ecuador. (Quito-Ecuador). https://orcid.org/0009-0003-4200-8609
6. Carlos Alejandro Fajardo Vargas. General Practitioner. Attached to the Carlos Andrade Marin Specialties Hospital. Graduated from Guayaquil State University. (Quito-Ecuador). https://orcid.org/0009-0005-8059-2361
7. Jarol Enrique Mizar Vega. General Practitioner. Attached to the Cerro Redondo Duran Health Center. Graduated from the State University of Guayaquil. (Salitre-Ecuador). https://orcid.org/0009-0009-9022-3075

ABSTRACT

Hirschsprung disease (HD), a congenital disorder characterized by the absence of ganglion cells in the intestines, presents a complex interplay of genetic, molecular, and clinical factors that significantly affect patient outcomes. As research continues, emerging therapies and innovative approaches show promise in improving treatment effectiveness and quality of life for affected individuals. This article seeks to provide an in-depth analysis of Hirschsprung disease, exploring its intricate pathophysiology, diagnostic methodologies and evolving treatment strategies, thereby contributing to a comprehensive understanding of this complex condition and its implications for clinical practice.

KEY WORDS

Hirschsprung’s disease, aganglionosis, intestinal motility disorders, diagnosis of Hirschsprung’s disease, and Hirschsprung’s disease treatment.

RESUMEN

La enfermedad de Hirschsprung (EH), un trastorno congénito caracterizado por la ausencia de células ganglionares en los intestinos presenta una interacción compleja de factores genéticos, moleculares y clínicos que afectan significativamente los resultados de los pacientes. A medida que avanza la investigación, las terapias emergentes y los enfoques innovadores se muestran prometedores para mejorar la eficacia del tratamiento y la calidad de vida de las personas afectadas. Este artículo busca proporcionar un análisis en profundidad de la enfermedad de Hirschsprung, explorando su intrincada fisiopatología, metodologías de diagnóstico y estrategias de tratamiento en evolución, contribuyendo así a una comprensión integral de esta compleja condición y sus implicaciones para la práctica clínica.

PALABRAS CLAVE

Enfermedad de Hirschsprung, aganglionosis, trastornos de la motilidad intestinal, diagnóstico de la enfermedad de Hirschsprung y tratamiento de la enfermedad de Hirschsprung.

INTRODUCTION

Hirschsprung’s Disease (HD), a congenital disorder characterized by the absence of ganglion cells in the intestines, presents a complex interplay of genetic, molecular, and clinical factors that significantly impact patient outcomes. The pathophysiology of Hirschsprung’s Disease is rooted in genetic mutations that disrupt the normal development of enteric neurons, leading to a lack of ganglionic cells in specific segments of the bowel, which in turn results in functional obstruction and a myriad of gastrointestinal symptoms. Understanding the molecular pathways involved in this disease is crucial, as it sheds light on potential targets for therapeutic intervention. Clinically, the diagnosis of HD hinges on the identification of characteristic symptoms such as chronic constipation, abdominal distension, and failure to thrive, alongside confirmatory tests including rectal biopsy, which provides definitive evidence of the absence of ganglion cells. Imaging techniques, such as contrast studies and ultrasound, further aid in evaluating the extent of the disease and guiding surgical planning. Treatment primarily involves surgical intervention to remove the affected bowel segments and restore normal function, but the postoperative course can be fraught with complications that necessitate careful management and follow-up. As research advances, emerging therapies and innovative approaches show promise for enhancing treatment efficacy and improving quality of life for affected individuals. This paper seeks to provide an in-depth analysis of Hirschsprung’s Disease, exploring its intricate pathophysiology, diagnostic methodologies, and evolving treatment strategies, thereby contributing to a comprehensive understanding of this complex condition and its implications for clinical practice.

OBJECTIVE

Provide an in-depth analysis of Hirschsprung’s disease, exploring its intricate pathophysiology, evolving diagnostic methodologies and treatment strategies.

METHODOLOGY

This scientific review aims to provide an in-depth analysis of Hirschsprung’s disease, focusing on its pathophysiology, diagnostic techniques, and treatment approaches. A systematic literature search is conducted across multiple databases, including PubMed, Scopus, and Web of Science, to identify relevant peer-reviewed articles, clinical studies, case reports, systematic reviews. The search strategy uses key terms such as «Hirschsprung’s disease», «aganglionosis», «intestinal motility disorders», «diagnosis of Hirschsprung’s disease» and «Hirschsprung’s disease treatment».

Inclusion criteria are applied to select studies that provide detailed insights into the pathophysiological mechanisms of Hirschsprung’s disease, including the absence of enteric ganglion cells in affected bowel segments, genetic mutations, and the role of neural crest cell development. Articles discussing variations in clinical presentation, ranging from neonatal bowel obstruction to chronic constipation, are also included. Diagnostic methods, particularly the use of rectal biopsy, barium enema, anorectal manometry, and newer techniques such as genetic testing, are evaluated based on their effectiveness and accuracy.

The review also places emphasis on treatment strategies for Hirschsprung’s disease, with a focus on both surgical and non-surgical approaches. Studies examining the outcomes of pull-through surgeries (e.g., Duhamel, Soave, and Swenson procedures) are analyzed, alongside those exploring post-operative complications such as enterocolitis, fecal incontinence, and constipation. Emerging therapeutic options, such as stem cell-based therapies and the role of minimally invasive techniques, are also considered for their potential to enhance patient outcomes.

All selected studies are assessed for their methodological rigor, sample size, and relevance to contemporary clinical practices. Studies that lack clarity in their methods or have limited applicability to the broader population are excluded. The collected data is categorized into three core themes: the pathophysiology of Hirschsprung’s disease, advances in diagnostic modalities, and treatment approaches. Special attention is given to articles that provide long-term follow-up results, as this information is critical for understanding the durability of treatment outcomes and patient quality of life.

This review synthesizes existing knowledge to provide a comprehensive understanding of Hirschsprung’s disease. It aims to inform clinical practice by highlighting the latest advancements in diagnosis and treatment, identifying gaps in current research, and suggesting potential directions for future investigation to improve patient care and outcomes.

RESULTS

Pathophysiology of Hirschsprung’s Disease:

What are the genetic factors contributing to Hirschsprung’s Disease?

Hirschsprung’s disease, a congenital condition characterized by the absence of ganglion cells in the distal colon, exhibits a complex genetic architecture that suggests both hereditary and sporadic cases. Predominantly, mutations in the RET proto-oncogene have been identified as a significant contributor to the disease, mapping to human chromosome 10q11.1¹. This gene encodes a protein tyrosine kinase that is crucial for the development of the enteric nervous system (ENS) derived from neural crest cells¹. The identification of RET mutations in both familial and sporadic cases underscores its central role in the pathogenesis of Hirschsprung’s disease¹. However, the presence of Hirschsprung disease in families without RET gene linkage indicates the involvement of additional genetic factors¹. This heterogeneity is further exemplified by the disorder’s classification as having autosomal dominant, autosomal recessive, and polygenic forms, with contributions from environmental factors as well¹. Consequently, genome-wide association studies (GWAS) have broadened the genetic landscape by identifying other loci, such as SEMA3 and NRG1, that harbor disease-susceptibility variants associated with Hirschsprung’s disease². These findings highlight the intricate interplay of multiple genes and their interactions, necessitating a comprehensive approach to unravel the full genetic basis of this condition. Understanding the multigenic nature and the role of modifier genes is essential in developing targeted interventions and genetic counseling for affected families³.

How does the absence of ganglion cells affect intestinal function?

The absence of ganglion cells in the intestine has profound implications for intestinal function, particularly highlighted in Hirschsprung’s disease. Ganglion cells are essential for the normal movement of stool through the intestines, and their absence leads to significant disruptions in bowel motility⁴. This disruption is due to the failure of the migration of enteric ganglion cells, which results in impaired innervation of the intestine⁵. Consequently, this impaired innervation manifests as varying degrees of aganglionosis, where sections of the bowel lack these critical nerve cells⁵. The presence of ganglion cells throughout the large intestine is crucial for maintaining healthy bowel function; their absence leads to a failure of proper muscle contractions necessary for the movement of stool, causing stool to remain in the large intestine [4][6]. This failure of normal bowel motility contributes to delayed passage of meconium, which is a cardinal symptom in over 90% of patients with Hirschsprung’s disease⁷. The accumulation of stool can cause severe complications, such as enterocolitis, which is marked by symptoms like fever, pain, and diarrhea, and occurs in about one-third of babies with Hirschsprung’s disease^4,7. Thus, the absence of ganglion cells not only leads to mechanical obstructions in the bowel but also significantly impacts overall gastrointestinal health, emphasizing the need for early diagnosis and intervention to manage this congenital condition effectively.

What are the associated molecular pathways involved in Hirschsprung’s Disease?

The intricate molecular pathways involved in Hirschsprung’s Disease (HSCR) are fundamental to understanding its pathogenesis, particularly as they relate to the formation and function of the enteric nervous system (ENS) ⁴. Central to these pathways is the disruption in the migration and differentiation of neural crest cells, which are vital for the proper development of the ENS⁴. Studies have shown that various gene modules related to signal transduction and its regulation play a significant role in this process, as confirmed by Pathway-Based Analysis (PBA) ⁴. Furthermore, there is considerable crosstalk and epistasis between these molecular pathways, indicating that they do not operate in isolation but rather in a network of interactions that collectively influence the disease phenotype. This dynamic interplay, which includes feedback interactions between enteric neural crest cells (ENCC) and the extracellular niche, is critical for the proper orchestration of ENS development⁴. These insights underscore the necessity of a comprehensive approach to studying HSCR, one that considers the multifaceted interactions within these molecular pathways to identify potential therapeutic targets and interventions⁴.

Diagnostic Methods for Hirschsprung’s Disease

What are the clinical symptoms commonly observed in patients with Hirschsprung’s Disease?

Hirschsprung’s Disease, a congenital condition resulting from the absence of neural crest-derived enteric ganglia in the terminal hindgut, manifests primarily through symptoms of intestinal obstruction⁸. In infants, this often presents as partial or complete obstruction within the first year of life⁸. As the child grows older, the clinical symptoms become more varied and can include chronic constipation and severe constipation which are hallmarks of the disease^4,9. Older children with Hirschsprung’s disease may also exhibit vomiting, abdominal swelling, and a reluctance to eat, which significantly impacts their nutritional status and overall well-being¹⁰. Additionally, these patients might suffer from diarrhea and an unusually foul-smelling stool, further complicating the clinical picture¹⁰. The distended abdomen is another common clinical symptom that, although not unique to Hirschsprung’s, is frequently observed and adds to diagnostic complexity⁴. These symptoms collectively illustrate the profound impact of the disease on the gastrointestinal system, necessitating early and precise diagnostic measures to differentiate it from other causes of constipation such as functional constipation⁸.

How is a rectal biopsy used to diagnose Hirschsprung’s Disease?

A rectal biopsy is a pivotal diagnostic tool for confirming Hirschsprung’s disease, primarily through the histological examination of tissue samples obtained from the rectum¹¹. The techniques employed in obtaining these biopsies significantly impact the conclusive rates and diagnostic accuracy. In the study under discussion, three biopsy techniques were compared: suction, punch, and open biopsies¹¹. The suction biopsy, while less invasive and often performed at the bedside, had a conclusive rate of 60%¹¹. In contrast, the more invasive punch and open biopsies had higher conclusive rates of 87% and 97%, respectively, highlighting their superior diagnostic reliability¹¹. Inconclusive results, primarily due to insufficient submucosa, varied significantly across these techniques, with suction biopsies showing the highest rate of inconclusiveness¹¹. Furthermore, the study underscores that rectal biopsies are generally safe procedures with minimal adverse effects reported, making them a viable option for pediatric patients¹¹. To enhance diagnostic accuracy, tissue samples are often stained with hematoxylin and eosin (HE) and reviewed by a blinded pathologist to assess for aganglionosis and nerve trunk hypertrophy¹². While the value of adding immunohistochemical (IHC) staining to conventional HE staining remains debated, it has been used to re-evaluate inconclusive biopsies, potentially reducing the need for re-biopsies¹². Given these findings, optimizing biopsy techniques and ensuring adequate tissue sampling are critical for accurate and reliable diagnosis, thus guiding appropriate therapeutic interventions for Hirschsprung’s disease.

What imaging techniques are most effective in the diagnosis of Hirschsprung’s Disease?

The effectiveness of imaging techniques in diagnosing Hirschsprung’s Disease (HD) lies in their ability to detect anatomical anomalies and functional abnormalities associated with the condition. A plain abdominal radiograph can be a useful initial diagnostic tool as it may show a dilated small bowel or proximal colon, indicating potential HD¹³. However, its utility can be limited in neonates and in cases of total colonic aganglionosis, where findings might appear normal even in affected individuals¹³. Contrast enema radiographs enhance diagnostic accuracy by revealing a «transition zone,» which marks the point where the normal bowel transitions to the aganglionic segment; this is a key indicator of HD¹³. The process involves careful observation of the dilated proximal colon juxtaposed with a normal-appearing distal colon, which becomes evident as the disease progresses¹³. Despite these advantages, contrast enemas also have limitations, particularly in the first few months of life when radiographs may not show significant abnormalities¹⁴. Anal manometry complements these radiographic techniques by measuring the internal anal sphincter’s response to rectal distention, with the absence of relaxation being a hallmark of HD¹³. When comparing the efficacy of contrast enema and anal manometry, both techniques demonstrate similar sensitivity and specificity, making them reliable options for diagnosing HD¹³. Thus, a combination of these imaging modalities, alongside advancements in optical techniques, provides a comprehensive approach to accurately identifying Hirschsprung’s Disease at various stages of patient development.

Treatment Approaches for Hirschsprung’s Disease:

What surgical options are available for treating Hirschsprung’s Disease?

The surgical treatment of Hirschsprung’s disease encompasses various techniques, each tailored to the specific needs of the patient. One of the primary surgical options is the pull-through procedure, which involves removing the section of the colon lacking nerve cells and attaching the healthy part of the colon to the anus¹⁵. In cases where immediate pull-through surgery is not feasible due to complications like megacolon or perforation, an ostomy surgery may be performed initially to divert faecal flow and allow the patient to stabilize before a subsequent pull-through procedure¹⁵. Additionally, the Duhamel procedure, which creates a side-to-side anastomosis between the normal and aganglionic bowel, is another viable surgical option¹⁶. Other established techniques include the Soave procedure, which preserves the outer muscular layer of the bowel while removing the aganglionic mucosal layer, and the Swenson procedure, which involves resecting the aganglionic segment and directly connecting the remaining colon to the rectum¹⁶. These diverse surgical approaches underscore the importance of individualized treatment plans to achieve optimal outcomes for patients with Hirschsprung’s disease.

How do postoperative care and complications impact recovery?

Postoperative care plays a pivotal role in the recovery of patients with Hirschsprung’s disease (HD), directly influencing the incidence and management of complications. Effective postoperative management is crucial for addressing complications such as faecal incontinence, constipation, and enterocolitis, which can severely affect the quality of life for HD patients¹⁷. Structured follow-up, including regular appointments and telemedicine support, is essential to monitor bowel function, perineal skin condition, growth development, and potential episodes of enterocolitis¹⁸. Moreover, the choice of surgical technique, such as opting for an oblique anastomosis over a circular one, can reduce the risk of postoperative complications and improve recovery outcomes¹⁹. Therefore, a thoughtful and systematic approach to postoperative care not only mitigates the immediate complications but also ensures a better long-term prognosis for patients recovering from HD¹⁹.

What are the emerging therapies and future directions in the treatment of Hirschsprung’s Disease?

Emerging therapies for Hirschsprung’s Disease (HSCR) focus on the potential of stem cell therapy, an area that holds significant promise for future treatment avenues¹⁹. Researchers are particularly interested in using enteric nervous system (ENS) stem cells to repopulate the aganglionic bowel in children with HSCR, aiming to address the root cause of the disease by regenerating the missing ENS¹⁹. These stem cells can be harvested from the postnatal gut, specifically from mucosal biopsies collected during routine endoscopy, which alleviates previous clinical challenges associated with obtaining full-thickness gut tissue during surgery. Once transplanted, these cells are expected to migrate to the site of the endogenous ENS and differentiate into neurons and glial cells, potentially forming a mature and functional ENS in the affected gut tissue¹⁹. This approach not only offers a more curative solution compared to traditional surgical methods but also opens up new research areas, such as the optimization of cell selection, harvesting, and transplantation techniques to ensure successful outcomes¹⁹. Advances in understanding ENS development and its regulatory mechanisms are crucial for refining these therapies and translating laboratory findings into effective clinical treatments¹⁹. A multi-faceted approach that includes both cell-based and pharmacological interventions, combined with innovations in pediatric surgery, holds the potential to significantly improve the long-term prognosis for patients with HSCR.

DISCUSSION

The findings from this analysis of Hirschsprung’s disease (HSCR) reveal critical insights into the genetic underpinnings and clinical implications of this complex condition. The strong association of RET mutations with both familial and sporadic cases emphasize the gene’s pivotal role in the pathogenesis of HSCR, yet the observation of cases without RET linkage suggests a multifactorial genetic landscape that warrants further exploration. The identification of additional loci, such as SEMA3 and NRG1, through genome-wide association studies (GWAS) highlights the need for a comprehensive understanding of the genetic modifiers involved. This is crucial not only for elucidating the etiology but also for informing genetic counseling for families affected by HSCR. The absence of ganglion cells significantly disrupts bowel motility, resulting in clinical manifestations such as delayed meconium passage and chronic constipation, which can worsen as the child ages. These symptoms underscore the necessity for timely diagnosis and intervention, as delays can lead to severe complications like enterocolitis, which affects a substantial proportion of infants with HSCR. Furthermore, the discussion of various surgical techniques, including the choice between oblique and circular anastomosis, points to the importance of individualized treatment strategies that can mitigate postoperative complications and enhance recovery. Structured follow-up care, involving regular assessments and telemedicine support, is vital for monitoring ongoing health issues such as faecal incontinence and growth development. However, the study acknowledges limitations, such as the variability in biopsy techniques and their impact on diagnostic accuracy, which could influence treatment decisions and outcomes. Future research should focus on refining diagnostic methods and exploring the potential of stem cell therapy as a transformative approach to treatment. Additionally, understanding the intricate molecular pathways of the enteric nervous system will be essential for developing targeted interventions that address the root causes of HSCR rather than merely managing symptoms. Overall, these findings contribute to the growing body of knowledge surrounding Hirschsprung’s disease, emphasizing the need for a multidisciplinary approach that integrates genetic, surgical, and supportive care strategies to improve patient outcomes.

CONCLUSIONS

Hirschsprung’s disease is a complex congenital condition characterized by the absence of enteric ganglion cells in parts of the colon, resulting in severe intestinal motility dysfunction. The pathophysiology of the disease is now better understood, with significant progress made in identifying the genetic mutations and developmental disruptions responsible for aganglionosis. Despite this progress, the exact mechanisms underlying neural crest cell migration failures remain an area of active research. A deeper understanding of these processes is crucial for advancing both diagnostic techniques and treatment strategies.

Diagnosis of Hirschsprung’s disease relies on a combination of clinical assessment and diagnostic tools, with rectal biopsy considered the gold standard for confirming the absence of ganglion cells. Other techniques, such as barium enema and anorectal manometry, remain valuable in the diagnostic workup, while newer approaches like genetic testing show promise in identifying familial cases and improving early detection. However, challenges in early and accurate diagnosis, particularly in atypical cases or short-segment disease, persist. Future advancements in diagnostic methods could further reduce diagnostic delays and improve outcomes.

Surgical intervention remains the primary treatment for Hirschsprung’s disease, with the pull-through procedure being the most widely used approach. While surgical outcomes are generally favorable, a significant number of patients experience post-operative complications, including enterocolitis, fecal incontinence, and constipation, which can have long-term impacts on quality of life. Efforts to refine surgical techniques, reduce complications, and improve post-operative care are ongoing, with promising developments in minimally invasive procedures and stem cell therapies that may offer alternative or adjunct treatment options in the future.

FUTURE DIRECTIONS

While substantial progress has been made in understanding, diagnosing, and treating Hirschsprung’s disease, challenges remain, particularly in addressing long-term complications and improving patient outcomes. Continued research into the genetic and molecular basis of the disease, as well as advancements in less invasive diagnostic and therapeutic techniques, will be key to advancing care for patients with this condition. A multidisciplinary approach that combines surgical expertise, early diagnosis, and comprehensive post-operative management is essential to improving the overall prognosis for those affected by Hirschsprung’s disease.

REFERENCES

1. Marx SJ, Wells SA. Multiple Endocrine Neoplasia. Elsevier eBooks [Internet]. 2011 Jan 1 [cited 2024 Mar 26];1(1):1728–67. Available from: https://doi.org/10.1016/b978-1-4377-0324-5.00041-9
2. Wagner JP, Shekherdimian S, Lee SL. Hirschsprung Disease: Background, Pathophysiology, Epidemiology. eMedicine [Internet]. 2021 Aug 2 [cited 2024 Oct 21];1(1). Available from: https://emedicine.medscape.com/article/178493-overview?form=fpf
3. Wallace AS. Genetic interactions and modifier genes in Hirschsprung’s disease. World Journal of Gastroenterology [Internet]. 2011 [cited 2024 Oct 21];17(45):4937. Available from: https://doi.org/10.3748/wjg.v17.i45.4937
4. Boston Children’s Hospital. Hirschsprungs Disease [Internet]. www.childrenshospital.org. 2023 [cited 2024 Oct 21]. Available from: https://www.childrenshospital.org/conditions/hirschsprungs-disease
5. Thakkar H, Curry J. Hirschsprung’s disease. Paediatrics and Child Health [Internet]. 2020 Oct [cited 2024 Oct 21];30(10):341–4. Available from: https://doi.org/10.1016/j.paed.2020.07.001
6. Mayo Clinic. Hirschsprung’s disease [Internet]. Mayo Clinic. 2019 [cited 2024 Oct 21]. Available from: https://www.mayoclinic.org/diseases-conditions/hirschsprungs-disease/symptoms-causes/syc-20351556
7. 7Puri P, Tomuschat C, Nakamura H. Hirschsprung’s Disease. Springer eBooks [Internet]. 2017 Jan 1 [cited 2024 Oct 21];1(1):1–20. Available from: https://doi.org/10.1007/978-3-642-38482-0_74-1
8. Camilleri M. Disorders of Gastrointestinal Motility. Elsevier eBooks [Internet]. 2012 Jan 1 [cited 2024 Jul 15];1(1):862–8. Available from: https://doi.org/10.1016/B978-1-4377-1604-7.00138-X
9. Lotfollahzadeh S, Taherian M, Anand S. Hirschsprung Disease [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2021 [cited 2024 Oct 21]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562142/
10. The Children’s Hospital of Philadelphia. Hirschsprung’s Disease [Internet]. www.chop.edu. 2014 [cited 2024 Oct 21]. Available from: https://www.chop.edu/conditions-diseases/hirschsprung-s-disease
11. Vervloet G, De Backer A, Heyman S, Leyman P, Van Cauwenberge S, Vanderlinden K, et al. Rectal Biopsy for Hirschsprung’s Disease: A Multicentre Study Involving Biopsy Technique, Pathology and Complications. Children (Basel) [Internet]. 2023 Aug 31 [cited 2024 Jan 17];10(9):1488–8. Available from: https://doi.org/10.3390/children10091488
12. Hviid E, Bjørn N, Ellebæk MB, Christensen L, Qvist N. Full-Thickness Rectal Biopsy in Children Suspected of Having Hirschsprung’s Disease: The Inconclusive Biopsy. Children (Basel) [Internet]. 2023 Sep 28 [cited 2024 Jan 19];10(10):1619–9. Available from: https://doi.org/10.3390/children10101619
13. Kessmann J. Hirschsprung’s Disease: Diagnosis and Management. American Family Physician [Internet]. 2006 Oct 15 [cited 2024 Oct 21];74(8):1319–22. Available from: https://www.aafp.org/pubs/afp/issues/2006/1015/p1319.html
14. Szylberg Ł, Marszałek A. Diagnosis of Hirschsprung’s disease with particular emphasis on histopathology. A systematic review of current literature. Gastroenterology Review [Internet]. 2014 [cited 2024 Oct 21];5(9):264–9. Available from: https://doi.org/10.5114/pg.2014.46160
15. National Institute of Diabetes and Digestive and Kidney Diseases. Treatment for Hirschsprung Disease [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases. 2021 [cited 2024 Oct 21]. Available from: https://www.niddk.nih.gov/health-information/digestive-diseases/hirschsprung-disease/treatment
16. Children’s National Hospital. Treatment Options for Children with Hirschsprung’s Disease [Internet]. Children’s National Hospital. 2024 [cited 2024 Oct 22]. Available from: https://www.childrensnational.org/get-care/departments/colorectal/provider-resources/treatment-options-for-hirschsprung-disease
17. Gao T, Xu W, Sheng Q, Xu T, Wu W, Zhibao Lv. Clinical outcomes and risk factors for postoperative complications in children with Hirschsprung’s disease. American Journal of Translational Research [Internet]. 2022 Jul 15 [cited 2024 Oct 22];14(7):4830. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9360846/
18. Lindert J, Schulze F, Märzheuser S. Bowel Management in Hirschsprung Disease—Pre-, Peri- and Postoperative Care for Primary Pull-Through. Children [Internet]. 2024 May 1 [cited 2024 Oct 21];11(5):588. Available from: https://doi.org/10.3390/children11050588
19. Munnangi P, Sayed Mushir Ali A, Deva S, Kushwaha V, Srivastava S, Boini A, et al. Post-surgical Outcomes of Different Surgical Techniques in Hirschsprung’s Disease: A Literature Review. Cureus [Internet]. 2023 Oct 1 [cited 2024 Oct 21];15(10): e47012. Available from: https://doi.org/10.7759/cureus.47012